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Abstract Recent decades have witnessed increasing possi-
bilities for genetic testing and screening. In clinical genetics,
the doctor’s office defined a secluded space for discussion of
sensitive reproductive options in cases of elevated risk for
genetic disorders in individuals or their offspring. When
prenatal screening for all pregnant women became conceiv-
able, the potential increase in scale made social and ethical
concerns relevant for the whole of society. Whereas genetic
testing in clinical genetic practice was widely accepted,
prenatal screening at a population level met with unease.
Concerns were raised regarding social pressure to screen: the
sum of individual choice might result in a ‘collective
eugenics’. The government’s involvement also raised suspi-
cion: actively offering screening evoked associations with
eugenic population policies from the first half of the 20th
century. By reconstructing elements of policy and public
debate on prenatal screening in the Netherlands from the past
30 years, this article discusses how the government has
gradually changed its role in balancing the interest of the
individual and the collective on genetic reproductive issues.
Against a background of increasing knowledge about and
demand for prenatal screening among the population, gov-
ernmental policy changed from focusing on protection by
banning screening toward facilitating screening in a careful
and ethically sound way by providing adequate information,
decision aids and quality assessment instruments. In the
meanwhile, invigorating democracy in public debate may
entail discussing concepts of ‘the good life’ in relation to
living with or without impairments and dealing with genetic
information about oneself or one’so f f s p r i n g .
Keywords Genetic screening.Prenatal screening.
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Introduction
In the years 2010 and 2011, revolutionary steps in
noninvasive prenatal diagnosis (NIPD) were reported. It is
now possible to sequence cell-free foetal DNA in maternal
serum to detect Down syndrome, and in principle, it should
also be possible to detect many more genetic disorders
(Chiu et al. 2011;L oe ta l .2010; Fan and Quake 2010).
Although the first proof-of-principle NIPD tests are
especially targeted at women who have high risk of
carrying a foetus with Down syndrome, it is envisaged that
in the near future such tests would become available for all
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DOI 10.1007/s12687-011-0063-zpregnant women. The uptake of diagnostic testing is
currently partly constrained because of the risk of iatrogenic
abortion induced by invasive chorionic villus sampling or
amniotic fluid test. To date serum screening can only assess
risk for neural tube defects and Down syndrome. If these
risk assessment tests were replaced by highly reliable
noninvasive tests more women might opt for testing. Would
NIPD testing become routinely available, this would mean
a new phase in a long process of increasing possibilities to
detect foetal abnormalities in pregnant women that started
in the 1950s.
Whenever new technological options, such as genetic
tests, become available often political and public debates
are called for to discuss the social and ethical ramifications.
The advent of NIPD led a commentator in the journal
Nature to state: ‘That possibility challenges all societies to
decide for which ends and by what means they want such
tests to be used’ (Greely 2011). Similar debates took place
in earlier phases of introducing and expanding prenatal
genetic testing and screening. In this article, we will reflect
on the dynamics of the discussion on these issues in the
Netherlands during the past 30 years. Whereas other
authors have written on prenatal screening in the Nether-
lands (Stemerding and van Berkel 2001; Toom and van
Berkel 2003; Popkema and Harbers 2005; Meijer et al.
2010) and we have outlined these discussions before (van
El et al. 2010a),
1 the focus of this account will be on the
tension between individual considerations versus collective
ramifications regarding certain technologies. Whereas re-
production is key to any society, balancing the tension
between the interest of the individual and the collective
regarding genetic reproductive issues is a delicate issue in
modern democracies and a challenge for governmental
policy making. The use or misuse of genetics by individ-
uals or institutions in the first half of the previous century
still sets the background of present-day arguments.
2 The
Netherlands is well-suited for a case study to explore
balancing this tension. The country has an up-to-date health
care system providing adequate basic services to the whole
population while enabling the provision of extra services of
personal preference; thereby, there is a mix of continental and
American health care systems. The Dutch public domain has
elements of Christian moral principles as well as social–
democraticandmoreliberalinfluences,necessitatingdialogue
and seeking consensus. This public domain operates at a
relativedistancefromthe government. Coalitiongovernments
trytorespecttheviewsoftheirrankandfilesupportersaswell
asintegratevariousstandpointsintogenerallyacceptedpolicy.
For our research, we interviewed stakeholders, organised
a so-called witness seminar with 20 stakeholders who had
been active in genetic testing or screening and/or related
policy issues (van El et al. 2010b), collected archival
material, studied the clippings archive of VU University
and collected articles in Dutch medical journals on the
subject of genetic testing and screening.
We will briefly discuss three occasions during the second
half of the 1980s on which genetic testing and screening for
reproductive issues became subject of wider attention, and
were discussed in medical journals, newspapers and/or
television programmes. In addition, we will discuss new
regulation during the 1990s, and changes in policy, as well
as public and professional views during the 2000s.
From genetic testing to genetic screening
The recent decades have witnessed increasing possibilities
for genetic testing and screening. In the Netherlands, since
the 1970s, individuals and their family members could
obtain genetic counselling for their own risk or diagnosis of
a serious genetic disorder or that of their offspring. At this
time, a foundation was laid for what was later to become
the specialty of clinical genetics (Nelis 1998). Consensus
on the standards of the developing profession was formu-
lated by a relatively small group of medical professionals
and experts of the Health Council of the Netherlands (1977;
1980) and was supported by representatives of emerging
patient organisations. In the intimacy of the consultation
room, a secluded space was defined, where doctors and
patients could discuss sensitive reproductive options in case
of an elevated risk for genetic or congenital disorders.
During the 1980s, it became increasingly clear that new
techniques might enable mass screening of pregnant
women. Maternal serum screening tests were developed to
detect neural tube defects, and a few years later, Down
syndrome, in a foetus. This potential increase of scale
meant that discussions on reproductive options were no
longer confined to the secluded space of a doctor–patient
relationship, but that prenatal testing and screening had
become relevant issues for the whole society.
Discussing genetic testing and screening
for reproductive issues
Better than God
In the Netherlands, the public awareness of developments
in genetic research and testing was greatly influenced by a
documentary series, Better than God, which appeared on
television in 1987. The series discussed ongoing develop-
1 The publisher, Profil Verlag, Munchen/Wien, has given permission to
reproduce parts of this book chapter.
2 The choice for this focus was inspired by the Genetics and
Democracy series organised in Lund, Sweden, where part of this
paper was presented on October 5, 2009.
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handicapped people would still be welcome in future society.
The series was discussed in newspapers, the director, Wim
Kayzer, was interviewed and the connection between modern
genetics and eugenic practices during the Second World War
was readily made by him and journalists (e.g. Pols 1987).
In this climate of increased awareness and anxiety about
developments in genetics, two reports on reproductive
issues appeared that stirred political and public discussion
setting the stage for the subsequent policies in the 1990s.
Prevention of hereditary and congenital anomalies
In December 1987, the Department of Health of the
Netherlands published a report on the prevention of
hereditary and congenital anomalies (Parliamentary
documentation 1987–1988a). The department wished to
formulate a comprehensive prevention policy by integrat-
ing knowledge of various forms of risk for the mother and
the foetus. These ranged from lifestyle issues (such as diet
and the teratogenic effects of substances such as alcohol,
tobacco and medicines), to infectious diseases. In doing
so, the department also responded to the World Health
Organization (WHO)’s initiative ‘Health for all by the
year 2000’ (WHO 1981) by calling upon national
governments to reduce morbidity and mortality. In an
effort to be comprehensive, the Department of Health
report included a section on the use of genetic services.
Genetic counselling was mentioned as one of several
measures to reduce morbidity and mortality, and abortion
of an affected foetus was circumscribed as a form of
‘secondary prevention’. Clinical genetic centres would enable
parents to enact ‘responsible parenthood’. The report stated
that people should decide for themselves what they meant by
that term, its meaning was not further elaborated. However,
the term was used in a section in which the societal cost or
burden was also mentioned in relation to ‘optimizing the
chance of a good outcome of reproductive behaviour’
(Parliamentary documentation 1987–1988a,3 4 –35). This
might have been perceived as a governmental viewpoint
favouring abortion as a cost-effective option.
The Parliament issued a call for reactions, after which
they received responses from among others the patient
organisation, as well as the professional organisation for
clinical geneticists. Several newspapers and magazines
covered the reactions to the report and the subsequent
debate in Parliament. An important objection to the report
for members of Parliament, clinical geneticists, journalists
and an ethicist, concerned the terminology, as genetic
services were associated with the notion of ‘responsible
parenthood’, and ‘optimizing the outcome of reproductive
behaviour’. Interestingly, in the 1970s some of the same
terms had been used without stirring controversy, such as
the term ‘responsible parenthood’. The fact that genetic
counselling was placed more explicitly under the heading
of prevention policy, as well as raised awareness due to the
documentary series, may explain the difference in response
(van El et al. 2007, 2010a,b). In addition, the suggested aim
of genetic counselling to reduce morbidity and mortality
raised criticism. In genetic counselling, it is essential that
patients be adequately informed so they can choose for
themselves (informed decision making) whether or not to
test and consider aborting an affected foetus in accordance
with their own values and personal circumstances. Al-
though reduction of the number of children born with a
handicap may be an effect of genetic counselling, it is
clearly not its aim, as was argued by an ethicist and
secretary of the Health Council (De Wert and Engel 1988).
Unintentionally, the impression had been raised that the
government wanted to use genetic services to improve
public health and reduce the costs of health care through
preventive abortion of foetuses with severe handicaps.
Members of Parliament and journalists wondered whether
the government might be considering eugenic policies,
and were concerned that people should still have the
right not to be tested (Reformatorisch Dagblad 1988). In
May 1988, the Minister and State Secretary of Health
reassured the members of the Parliamentary Standing
Committee on Health that there was no need to be
concerned about the government’s policy on prenatal
testing and the position of handicapped people in Dutch
society. The birth of a handicapped child would never be
regarded as a case of failed prevention (Parliamentary
documentation 1987–1988b).
The arguments in the public debate show that it was
deemed problematic to subsume prenatal testing or screen-
ing and abortion under the heading of a prevention policy.
A more careful policy was suggested to accommodate the
specific sensitivities and requirements for various kinds of
screening (Parliamentary documentation 1987–1988c). As a
consequence of these discussions in governmental docu-
ments, more attention was given to terminology. Ethicists at
the Ministry of Health became more closely involved in
preparing policy documents.
Prenatal screening
In the beginning of the 1980s, the Health Council of the
Netherlands was asked to report on the possibilities for
prenatal screening. Screening tests had become available to
measure the level of alpha foetoprotein in maternal blood as
an estimate of the risk of the foetus having a neural tube
defect. By the end of 1988, the Health Council of the
Netherlands (1988) published a report advising the govern-
ment to start a pilot programme for serum screening.
However, the advice was not unanimous. An influential
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was the first chairman of the committee preparing the
report, but stepped aside and published a minority
standpoint at the end of the report (Health Council of the
Netherlands 1988). One of his concerns was that the
decentralised organisation of prenatal care in the Nether-
lands, mostly in the hands of midwives in primary care, left
little time for retesting and follow-up after the first
screening test in the sixteenth week of pregnancy. He also
considered the bad test characteristics as problematic as
false positive outcomes could cause unnecessary anxiety in
pregnant women. Another issue that was brought up by him
on various occasions was the fact that the risk assessment
of genetic screening tests did not meet the standards of
prenatal diagnosis. He was concerned that the public trust
in genetic counselling and prenatal diagnosis—something
that he had carefully helped to establish in the previous
years—would be undermined (van El et al. 2010a,b).
In 1989, the Dutch government decided not to imple-
ment maternal serum screening for neural tube defects
(Parliamentary documentation 1989–1990a). The decision
was based on the WHO criteria written by Wilson and
Jungner (1968). The test characteristics were found to be
inadequate; there were too many false positives and false
negatives. Since there was no treatment available, the
criterion that only treatable disorders should be screened
was not met. The test was considered to be unacceptable
for the Dutch population. In a case of a positive test
result, further invasive testing might cause an iatrogenic
abortion. This was an ethical limit the government did
not want to cross. Furthermore, psychological strain and
medicalisation were mentioned as casting shadows over
the ‘joyful period of pregnancy’. The government
explicitly mentioned its concern that pressure from health
care workers or public opinion might constrain the
option of not taking a test. The government’s involve-
ment might exert an ‘important influence’ in that respect
(Parliamentary Documentation 1989–1990a). In Parlia-
ment, all parties from the left to right wing, including
parties representing Christian denominations supported
the government’s decision not to implement screening
(Parliamentary Documentation 1989–1990b).
Dutch obstetric health care professionals were divided
concerning the screening test. In the north of the Nether-
lands, screening had been offered on a small scale on a
research basis. Obstetricians in that area had expected to
continue or expand that practice. In 1990, at an obstetric
conference to which foreign experts had been invited, pleas
were made regarding serum screening (Mantingh et al.
1991). In the Dutch Journal for Midwives, the subject was
heavily debated. The professional organisation, the Dutch
Society of Obstetrics and Gynaecology, decided not to
support serum screening.
Patient organisations were also divided. The Council for
Handicapped People (Gehandicaptenraad) did not favour
prenatal genetic screening, but the patient organisation for
children with spastic disorders, BOSK, which included a
group of parents of children with neural tube defects, was
interested in the test, in principle.
Meanwhile, it had become clear that the test for neural
tube defects could also be used to assess the risk for Down
syndrome, namely by detecting low levels of alpha
fetoprotein. A new round of governmental enquiry and
requests for research began. In 1992, the Ethical Committee
of the Department of Health advising on research applica-
tions (KEMO) was asked to consult on a project of the
obstetricians in the northern and central regions of the
Netherlands to offer screening for neural tube defects and
Down syndrome and study the ethical and psychological
aspects of such screening. KEMO had no ethical objections
to this type of research. However, it mentioned that this
might actually not be seen as population screening in the
sense of an offer without a prior medical condition. Since
the women were pregnant they were already receiving
medical care. Furthermore, it was suggested that women
might be informed about the test so they could make their
own decision about it; thus reducing pressure to take the
test (KEMO 1992). The same point of view was voiced by
the parents’ organisation BOSK (BOSK 1992). The
organisation wanted women of all ages to be informed
about the test so they could decide for themselves.
However, BOSK was concerned informed consent would
not be guaranteed in case screening would be offered as
part of a population screening programme; the free choice
not to opt for abortion might be constrained through societal
pressure. As we will discuss below, this distinction between
offering and informing would become important in the next
decade. The Minister, however, decided not to implement
serum screening for Down syndrome in the early 1990s.
Testing for reproductive issues versus population
screening
The discussion on serum screening should be seen in the
light of previous developments during the 1980s. As
became clear in the discussions about the departmental
report on the prevention of hereditary and congenital
anomalies (Parliamentary documentation 1987–1988a),
there was a strong consensus for government to keep its
distance from prenatal genetic testing. In clinical genetic
practice in the Netherlands, parental autonomy had been
firmly established. It appeared that by then a ‘field of
argumentation’ had developed regarding genetic testing for
sensitive reproductive options. On the other hand, quite
another field of argumentation had formed concerning
82 J Community Genet (2012) 3:79–89population screening. There was consensus at the time that
the instrument of population screening should be solely
offered to improve public health if used for treatable
disorders with an available early intervention. In short: no
treatment, no screening. In this field of argumentation, the
government should play an active role.
Prenatal screening did not fit either of these two fields of
argumentation, and in the decades to come in political and
professional debates, a new field was constructed by
alternatively borrowing and differentiating from the fields
of argumentation of both prenatal testing and population
screening. How this process works can, for instance, be
seen by looking at the role of the government. Fear of
governmental pressure, as well as societal pressure appeared
indiscussionsonprenatalgeneticscreening.Theveryfactthat
the government would organise and offer screening was
perceived as exerting pressure. This line of thinking was
further elaborated in the report ‘Genes and limits’ published
by the Scientific Institute of the Christian-democratic party,
CDA, in 1992. This political party was influential because
during the 1980s and first half of the 1990s it had formed
coalition governments chaired by prime ministers from the
CDA. The report expressed the Christian-democratic view-
point on modern genetic technologies and stated:
‘Population screening is aimed at potential prevention or
treatment of disease … in any case it may be perceived by
citizens … that the government by allowing population
screening, would find it important … to detect affected
foetuses without prevention or treatment being available…’
(Scientific Institute of the CDA 1992). Also, preconceptional
carrier screening was not found to be acceptable as it would
burden the future parents with uncertain knowledge, and
would eventually lead to a decision on whether or not to
become pregnant and continue that pregnancy or terminate it.
For the time being, reproductive issues were deemed to
be safely in the hands of obstetricians and clinical
geneticists in the case of elevated risk, such as advanced
maternal age. Prenatal diagnostic testing was offered to
women of and over 36 years of age. For this group in the
1990s, serum screening gradually became an option.
Though serum screening might be used as an additional
or better risk assessment instrument than maternal age,
ethical concerns were considered too significant. For
pregnant women in general, serum screening was unavail-
able during the 1990s, thereby precluding parental auton-
omy to choose screening (Weinans et al. 2000).
New regulation
In 1996, the Population Screening Act (WBO: Wet op het
Bevolkingsonderzoek), debated for many years, finally
came into force. The purpose of the Act was to protect
people against potentially harmful screening. A special
license was required to organise some forms of screening,
such as population screening for disorders with no available
treatment orprevention. For the latter, alicence would onlybe
given in ‘exceptional circumstances.’ The Act underscored
that treatability was a cornerstone of Dutch screening policy.
The Health Council of the Netherlands reflected on the
new legal framework and the fact that prenatal screening
would be subject to licensing in the absence of treatment or
prevention. When discussing the legislator’s viewpoint that
pregnancy termination constituted neither treatment nor
prevention, the committee stated that abortion nevertheless
could be seen as an appropriate course of action, under the
circumstances (Health Council of the Netherlands 1994,
76). Clinical geneticist Leo ten Kate, one of the Council
committee members, later noted:
‘The committee considered that “genetic screening
should enable people to escape their fate by giving them
the freedom to make an informed choice and adopt a
chosen course of action which they regard as acceptable”…
By taking this position, the committee freed itself from the
restrictive viewpoint of the legislature and formulated a set
of criteria to be met by genetic screening programs’ (Ten
Kate 2000, 296). The Health Council report refined and
elaborated earlier screening criteria, such as those by
Wilson and Jungner (1968) and the Council of Europe
(Committee of Ministers 1992). For our purpose, particu-
larly the formulation of criteria 3 and 4 by the Health
Council of the Netherlands (1994) are relevant:
3. The purpose of the programme must be to enable the
participants to determine the presence or the risk of a
disorder or carrier status, and to take a decision on the basis
of that information.
4. Practical courses of action must be open to the
participants.
By introducing a new focus on ‘courses of action’,a
tension was created with the legal framework for population
screening that insisted on ‘treatment’ as point of reference.
By explicitly restricting mass screenings to disorders for
which a treatment was available, it was not clear what the
consequences were for current practice of Down syndrome
testing offered topregnantwomen ofand over36years.Since
testingwasperceived asindividualhealthcare,initially, itwas
expected to be exempt from licensing under the Population
Screening Act. In 1996, however, it was agreed that testing
based on maternal age should be considered as screening,
since the test was not requested by an individual woman, but
ratherwasofferedtoaspecificgroupofwomen(Parliamentary
Documentation 1995–1996). Because this kind of genetic
testing by then had become standard practice, prenatal testing
for Down syndrome for women of and over 36 years of age
was granted a temporary licence.
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After the turn of the century, developments in screening
techniques, improvements in test characteristics, and a
gradually rising interest in prenatal screening put the
subject on the agenda again. For women of and over
36 years of age, it had become possible to have a serum
screening test, women under 36 years of age could ask for
one, which increased familiarity with prenatal screening.
Having prenatal ultrasound screening ‘for fun’ became a
new phenomenon that was discussed in women’s maga-
zines. Around the year 2000, pilots were conducted with
nuchal translucency and serum screening (van den Berg et
al. 2005). New technological options and the implications
for policy were discussed in the 2001 Health Council report
‘Prenatal Screening’ and its 2004 follow-up ‘Prenatal
screening (2)’ (Health Council of the Netherlands 2001,
2004). In 2001, the Health Council reviewed several
screening test methods. A triple test to be offered in the
second trimester of pregnancy was considered as a suitable
risk assessment screening for both Down syndrome and
neural tube defects and should be aimed at all pregnant
women, regardless of age. According to the Heath Council,
when certain conditions were met, such as an adequate
procedure for informed consent, risk assessment for Down
syndrome would be ‘such a superior alternative to the
existing practice of maternal age-based screening that there
should be no reason to delay its introduction any longer’.
The Council argued that screening based on the triple test
would lead to considerably fewer invasive tests and
increased detection of Down syndrome pregnancies, while
a far larger group would be allowed to benefit from having
individual risk assessment. The introduction of screening
for neural tube defects was considered a desirable step
(Health Council of the Netherlands 2001,2 8 –29).
At the end of 2001, the Ministry of Health organised a
Consultation round inviting several groups, such as
obstetricians and patient representatives, to voice their
opinions on serum screening (Toom and van Berkel
2003). In the same year, several obstetricians criticised the
Health Council’s report in a medical journal. An important
point of contention was that the birth prevalence of Down
syndrome was higher in the maternal age group over
36 years of age. According to these obstetricians, by setting
an age limit, potential psychological harm from screening
younger women could be prevented (Hamerlynck and
Knuist 2001). Another argument was that test character-
istics for the group of older women were better than for the
group of younger women. The number of false negatives in
women under 36 years of age was found unacceptably high:
approximately half of the cases of Down syndrome in
pregnancies of younger women would not be detected,
thereby giving false reassurance. In addition, the false
positives in the younger age group would require further
testing. Based on figures from the Health Council, the
obstetricians calculated that via invasive testing about the
same number of cases of Down syndrome would be
detected (115) as healthy foetuses would be lost because
of test-induced iatrogenic abortions (111). Medicalisation of
pregnancy was deemed undesirable (Kleiverda and Vervest
2001). The Health Council Committee had based its argu-
ments on calculations for all age groups together. Representa-
tives of the Committee responded by stating that compared to
the current age-related diagnostic testing, the total number of
invasive tests would drop. For the Committee, the option for
women of all ages to consider a test was important (Van der
Maas and Dondorp 2001) and was seen as a benefit, whereas
the obstetricians stressed the burden of testing.
Offer screening only to 36+ women?
In November 2003, the State Secretary of Health sent a
letter with the government’s reaction to the Health Council.
In the statement, several arguments from previous years
reappeared. The intention of the Population Screening Act
to protect people against the potential drawbacks of
screening was underscored. According to the State Secre-
tary, the drawbacks of risk assessment screening for women
under 36 years of age were considered greater than the
benefits because their chance of having a foetus with Down
syndrome was lower than for older women; medicalisation
of childbirth for this group was to be avoided. Women over
36 years of age should be offered screening tests, as well as
invasive diagnostic tests. If women under 36 years of age
wanted a risk assessment test, they could ask and pay for it
themselves. The State Secretary remarked that there were
ample reasons to continue the restrained government policy
regarding prenatal screening. She stated it confronts us with
questions such as, whether medical framing of a natural
process should be applied that ‘hardly’ raises problems for
younger women, and that is seen by most of them as
something positive; and whether this is a step towards a
misleading ideal of a malleable humanity? (Parliamentary
documentation 2003–2004a).
The danger of eugenics in population screening
In the arguments of the State Secretary and commentators,
such as critical obstetricians, age limit surfaces as a
watershed for population screening. In general, for popula-
tion screening, benefit must outweigh harm (Wilson and
Jungner 1968). The Health Council weighed the benefits of
having the option to obtain risk assessment against potential
harm for all pregnant women, whereas the State Secretary
and critical obstetricians split pregnant women into subsets.
When weighing pros and cons for younger women, it was
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suffer from the psychological burden whereas their group
risk was relatively small. However, the figures may relate to
a more fundamental principle. Pregnancy is seen as a
natural phenomenon and medicalisation of pregnancy in the
form of prenatal testing places pregnancy in a category of
potential danger. A moral argument is added: the question
whether we consider life to be malleable and appropriate for
tinkering. Here, we find an echo of the fears of eugenics.
Whereas testing in individual high risk cases is more or less
accepted, on a population level, prenatal screening can cause
discomfort. The fact that the government would organise
screening added to that sentiment (as discussed in the
section above). People might think that particular screening
would be acceptable and advisable in the interest of public
health. The government could avoid using the instrument of
population screening by maintaining the age limit and not
offering serum screening to all pregnant women. Restricting
screening to women 36 or older would fit into the existing
paradigm of providing genetic services to persons with an
elevated risk. What is relevant from a democratic point of
view is that the government then makes the decision for
younger women who cannot decide for themselves whether
to have the screening test or not.
Freedom to take the screening test
In contrast to the discussion at the end of the 1980s, in the
early 2000s, in Parliament and in the media, some critical
questions were raised in response to the government’s
position. Especially problematic was the issue that women
under 36 years of age had to ask for the test themselves, as
the government was under no obligation to inform them of
its availability nor was it possible to apply for reimburse-
ment of the cost for the test. For women who lacked
financial resources, had a lower education or a poor
understanding of the Dutch language it would be difficult
to have a test (Parliamentary documentation 2003–2004b).
Also, a motion was brought forward urging the government
to offer prenatal screening to all women (Parliamentary
documentation 2003–2004c). In contrast to the reactions in
the 1980s, when concerns were raised about whether
women would have the option not to be tested, this time,
in parts of society there were concerns about whether
women would be able to have a test, if they wanted it.
In April 2004, the Health Council produced an updated
report on prenatal screening (Health Council of the
Netherlands 2004) and again suggested abandoning the
age limit. They now suggested performing a combination
test for Down syndrome in the first trimester—a blood test
and a nuchal translucency measurement by ultrasound. For
neural tube defects, an ultrasound test in the second
trimester would be preferred.
The State Secretary of Health responded to this new
advice and to the critical questions regarding her letter
explaining the government’s stand on the previous Health
Council report on prenatal screening. She argued that based
on new test developments giving information to all
pregnant women on risk assessment tests by now was
self-evident. However, women should have the option not
to be informed if they did not want to. It should be made
clear to women that they could reject screening, what the
consequences of having a risk assessment test could be, and
what further actions could take place in case of a positive
outcome. Then, the woman could reflect on whether she
would want to enter that trajectory at all. The restrained
policy was continued, as was the age limit. It was argued
that for women under 36 years of age, the risk of having a
child with Down syndrome was lower, and the test would
have more false positive and false negative outcomes than
for the group who were 36 years of age or older. It was
reiterated that it was not the aim to detect as many
abnormalities as possible. Parents of children with Down
syndrome or someone having Down syndrome should
never be questioned as to why there had not been prenatal
screening. For neural tube defects, the possibility of
performing an ultrasound in the second trimester was
studied further as recommended. The Health Council had
suggested doing so, and representatives of obstetricians and
midwives had urged to introduce this screening routinely,
among others to strengthen the quality of standard care
(Commissie Verloskunde 2003). Compared to the end of the
1980s, now there was support among health care profes-
sionals for prenatal screening for neural tube defects.
No treatment, no screening?
We would like to argue that these new policy developments
in prenatal screening for Down syndrome and neural tube
defects marked a shift from an emphasis on treatability and
collective protection against harm by banning screening.
Instead, offering options has moved to the fore as suggested
in 1994 by the Health Council. Women are now given a
choice, based on adequate information, to screen or not to
screen for disorders in their foetus for which no treatment
(in the sense of cure) is available. However, currently,
prenatal screening for Down syndrome is not offered as part
of an official population screening programme to women of
all ages. The information on the screening is provided to all
women, but women under 36 years of age have to pay for
the screening themselves.
To complicate the picture, a second trimester screening,
the standard anomaly scan (SEO: Structureel Echoscopisch
Onderzoek), was introduced in 2007. It is offered to all
pregnant women and reimbursed. Interestingly, this anomaly
scan can detect both treatable conditions, such as certain
J Community Genet (2012) 3:79–89 85cardiac anomalies, as well as untreatable conditions, such as
severe neural tube defects. The character of the technology
has made maintaining the strict separation between the field
of argumentation of population screening for health pur-
poses on the one hand and the field of argumentation of
genetic testing for untreatable disorders on the other hand
problematic.
3 By introducing this screening, in fact, a new
standard integrating elements of both fields of argumenta-
tion is developing.
Although the standard anomaly scan does not resolve
the conflicting aims of improving a foetus’ health outcome
versus gaining information about a possibly untreatable
disorder as a basis for reproductive options, the woman or
couple can decide whether or not to have the screening
t e s t .M u c ha t t e n t i o ni sp a i dt op r o v i d i n gw o m e nw i t h
adequate information about risk assessment testing, as well
as the option to decide not be informed or not to have the
screen. For Down syndrome screening, web-based decision
aids have been developed (Raats et al. 2008;M e i j e re ta l .
2010). This level of pretest information and counselling
echoes the principle of informed choice in clinical
genetics.
New trends
Since the 1980s, not only have techniques been devel-
oped that made it possible to screen an increasing number
of pregnant women for a growing number of disorders,
but public knowledge on and a demand for genetic testing
has also increased. Another development has been the
introduction of commercial testing. In the Netherlands, at
the end of the 1990s, commercial companies started to
offer so-called ‘ultrasounds for fun’, making it possible to
have intrauterine pictures of the foetus. The fact that
foetal anomalies were occasionally detected in the
presence of parents who had not received any counselling
was an extra impetus to regulate screening. Although a
range of genetic tests is currently offered on the internet
(Borry et al. 2010), until now prenatal testing has been
predominantly offered via established centres of health
care. However, the trend for commercialisation also
implies that the ‘old’ governmental policy of not offering
screening as a way to protect people against potential harm
is becoming obsolete. If certain tests are not offered by the
government, people may arrange to have testing in other,
perhaps commercial, centres or hospitals in other countries,
or via the internet.
Conclusion and discussion: Individual versus collective
effects
In this new era, the individual woman or couple has gained
more options to make an informed choice of whether or not
to have reproductive screening. In principle, the availability
of high-quality testing and the ability to make an informed
choice might be welcomed as a positive aspect of present-
day health care in modern democracies.
At the same time, it is relevant to note that individual
choices add up to a collective effect: reproductive screening
may become an increasingly ‘normal’ thing to do. Even if
societal pressure is not explicit, implicit norms, comments
and expectations from friends and family may frame the
choices individuals can make. The sum of the individual
choices may result in a ‘collective eugenics’ as visible in
the number of screening tests being performed and in the
reduction of the live births of foetuses with serious
disorders that can be detected prenatally.
This mechanism, which is a cause for unease, can be
demonstrated in other reproductive testing, such as Preim-
plantationGenetic Diagnosis (PGD) and willcertainly surface
again when new free foetal DNA testing is considered.
IntheNetherlands,in2008,PGDbecamethefocalpointof
a public debate and almost caused the downfall of the Cabinet
(Huijer 2009). PGD had been applied rather unproblemati-
cally on a very small scale, for a handful of couples with a
high risk of serious disorders in their offspring. When the
government prepared new regulation of this practice, a
public debate ensued in newspapers and on the television,
among other things, over the question of whether disorders
that are not fully penetrant, such as hereditary breast cancer,
would also be eligible for PGD. Although patient groups,
ethicists, and newspaper commentators, for instance, in the
liberal newspaper NRC (NRC 2008), pleaded for this
application pointing to the severity and high penetrance of
the disorder, most notably representatives of Christian
political parties and Christian patient groups called for a
ban on this type of testing, arguing for the right to life and
against eugenic tendencies (e.g. Kuiper 2008). Issues of
(expected) scale figured anew as did the notion of the
democratic right to make an informed choice (depicted as
opposed to a ‘religiously ordained’ morale).
Whenever new technological options in prenatal testing
become available, debate is called for to discuss the social
and ethical ramifications. Especially, the tension between
individual choice and the collective effects of creating a
society without room for handicaps or illness, as a new form
of collective eugenics, reappears. In the light of this tension,
we would like to draw upon our Dutch historical case study to
discuss the role of the government and public debate.
Evidently, the role and responsibilities of the government
have changed during the years. Instead of banning screening
3 Speaking of untreatable disorders in several cases is or has become
questionable, and it would be better to regard these disorders as treatable
‘to a lesser extent’. Recent advances in medication and care have made a
significant contribution to boosting quality of life and life expectancy by
tackling some aspects of the phenotype or co-morbidity.
86 J Community Genet (2012) 3:79–89that was found to be unsound and was perceived to have
negative societal consequences, the government increasingly
has taken up the responsibility to implement new forms of
reliable reproductive testing and screening in an ethically
sound manner, for instance, by providing adequate informa-
tion and enabling informed choice, thereby changing the
notion of protection. In addition, continuing efforts are
necessary to boost the quality of testing and personnel
performing the test. It is vital that policy should be in place
to ensure standards of care for the handicapped, in order for
people to have a real choice of whether to have testing or not,
an issue that had already been raised in an earlier Health
Council of the Netherlands (1989)r e p o r t .
In modern democracies, public debate is essential for
discussing values and practices implicated by governmental
policy. It should be possible to voice a range of arguments for
or against screening, and shed light on the mixed blessings
and complexities involved (see also Huijer (2009)). Until
recently, both human geneticists and bioethicists have
(rightfully) stressed the importance of taking the individual
as a focal point when considering genetic testing. Given the
recurrent argument of collective eugenics, public debate
might be used to reflect on the ramifications of individual
choice. Debate has just started on the host of ethical issues
involved in whole genome sequencing, including sequencing
of foetal DNA. Aside from the difficulty of analyzing and
interpreting the data, issues include determining what
information to report to parents and the right of the future
child not to know its genetic makeup (Health Council of the
Netherlands 2010;d eJ o n ge ta l .2010). Though this debate
still seems confined to small groups of experts, the expected
advent of free foetal DNA testing will soon open this debate
to a wider audience. If or when such testing becomes a
reality, the experiences with the standard anomaly scan might
hold important lessons as to the difficulties in counselling
and guiding parental reaction to information that may not
always be conclusive about the nature of the suspected
anomaly. In popular literature, accounts of how to deal with
prenatal screening and foetal anomaly scan information, and
how to live with the difficult decisions based on that
information are appearing (Slagboom 2011). For societal
actors, enriching public debate may entail discussing
concepts and accounts of living with or without impairments
and assimilating genetic information about oneself or one’s
offspring. These concepts change over time and instead of a
‘collectiveeugenics’,wemightbeabletodiscussandproduce
new collective, yet varying images of ‘the good life’.
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